Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER von Yardley, D A, Tripathy, D, Brufsky, A M, Rugo, H S, Kaufman, P A, Mayer, M, Magidson, J, Yoo, B, Quah, C, Ulcickas Yood, M

Volltext

Concordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831 von Roche, Patrick C., Suman, Vera J., Jenkins, Robert B., Davidson, Nancy E., Martino, Silvana, Kaufman, Peter A., Addo, Ferdinand K., Murphy, Bronagh, Ingle, James N., Perez, Edith A.

Volltext

Fast 3-D Tomographic Microwave Imaging for Breast Cancer Detection von Grzegorczyk, T. M., Meaney, P. M., Kaufman, P. A., di Florio-Alexander, Roberta M., Paulsen, K. D.

Volltext

impact of sharing results of a randomized breast cancer clinical trial with study participants von Partridge, Ann H, Wolff, A. C, Marcom, P. K, Kaufman, P. A, Zhang, L, Gelman, R, Moore, C, Lake, D, Fleming, G. F, Rugo, H. S, Atkins, J, Sampson, E, Collyar, D, Winer, E. P

Volltext

Abemaciclib with fulvestrant in patients with HR+, HER2- advanced breast cancer (ABC) that exhibited primary or secondary resistance to prior endocrine therapy (ET) von Grischke, E.-M., Neven, P., Lin, Y., Kaufman, P.A., Sledge, G.W.

Volltext

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer von Romond, Edward H, Perez, Edith A, Bryant, John, Suman, Vera J, Geyer, Charles E, Davidson, Nancy E, Tan-Chiu, Elizabeth, Martino, Silvana, Paik, Soonmyung, Kaufman, Peter A, Swain, Sandra M, Pisansky, Thomas M, Fehrenbacher, Louis, Kutteh, Leila A, Vogel, Victor G, Visscher, Daniel W, Yothers, Greg, Jenkins, Robert B, Brown, Ann M, Dakhil, Shaker R, Mamounas, Eleftherios P, Lingle, Wilma L, Klein, Pamela M, Ingle, James N, Wolmark, Norman

Volltext

Balixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial von Cortes Castan, J., Martín, M., Pernas Simon, S., Gomez Pardo, P., Lopez-Tarruella, S., Gil Martin, M., Manso, L.M., Ciruelos, E.M., Perez Fidalgo, J.A., Hernando, C., Ademuyiwa, F., Weilbaecher, K., Mayer, I.A., Pluard, T., Martinez Garcia, M., Vahdat, L.T., Wach, A., Barker, D., Romagnoli, B., Kaufman, P.A.

Volltext

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu von VALONE, F. H, KAUFMAN, P. A, WARDWELL, K, GUYRE, V, MORLEY, T. L, ARVIZU, C, FANGER, M. W, GUYRE, P. M, LEWIS, L. D, MEMOLI, V, YASHWANT DEO, GRAZIANO, R, FISHER, J. L, MEYER, L, MROZEK-ORLOWSKI, M

Volltext

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study von Harbeck, N., Rastogi, P., Martin, M., Tolaney, S.M., Shao, Z.M., Fasching, P.A., Huang, C.S., Jaliffe, G.G., Tryakin, A., Goetz, M.P., Rugo, H.S., Senkus, E., Testa, L., Andersson, M., Tamura, K., Del Mastro, L., Steger, G.G., Kreipe, H., Hegg, R., Sohn, J., Guarneri, V., Cortés, J., Hamilton, E., André, V., Wei, R., Barriga, S., Sherwood, S., Forrester, T., Munoz, M., Shahir, A., San Antonio, B., Nabinger, S.C., Toi, M., Johnston, S.R.D., O’Shaughnessy, J., Jimenez, M.M., Johnston, S., Boyle, F., Steger, G.G., Neven, P., Jiang, Z., Campone, M., Huober, J., Shimizu, C., Cicin, I., Wardley, A., Tolaney, S.M., Abuin, G.G., Zarba, J., Lim, E., Sant, P., Liao, N., Christiansen, B., Eigeliene, N., Martin-Babau, J., Ettl, J., Mavroudis, D., Chiu, J., Boer, K., Nagarkar, R., Paluch-Shimon, S., Moscetti, L., Sagara, Y., Kim, S.-B., Maciel, M.M., Tjan-Heijnen, V., Broom, R., Lacko, A., Schenker, M., Volkov, N., Sim Yap, Y., Coccia-Portugal, M., Ángel García Sáenz, J., Andersson, A., Chao, T.-Y., Gokmen, E., Harputluoglu, H., Berzoy, O., Patt, D., McArthur, H., Chew, H., Chalasani, P., Kaufman, P., Tedesco, K., Graff, S.L.

Volltext

The v-rel oncogene: insights into the mechanism of transcriptional activation, repression, and transformation von WALKER, WH, STEIN, B, GANCHI, PA, HOFFMAN, JA, KAUFMAN, PA, BALLARD, DW, HANNINK, M, GREENE, WC

Volltext

Nuclear expression of the 50- and 65-kD rel-related subunits of nuclear factor-κB is differentially regulated in human monocytic cells von KAUFMAN, P. A, WEINBERG, J. B, GREENE, W. C

Volltext

360PSystemic therapy in second-line metastatic triple negative breast cancer (mTNBC): A systematic literature review (SLR) and meta-analysis (MA) of efficacy von Kaufman, P A, Kwon, C S, Feliciano, J, Westley, T, Forsythe, A, Garfin, P, Brown, L

Volltext

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III von Kaufmann, Petra, Thompson, John L.P., Levy, Gilberto, Buchsbaum, Richard, Shefner, Jeremy, Krivickas, Lisa S., Katz, Jonathan, Rollins, Yvonne, Barohn, Richard J., Jackson, Carlayne E., Tiryaki, Ezgi, Lomen-Hoerth, Catherine, Armon, Carmel, Tandan, Rup, Rudnicki, Stacy A., Rezania, Kourosh, Sufit, Robert, Pestronk, Alan, Novella, Steven P., Heiman-Patterson, Terry, Kasarskis, Edward J., Pioro, Erik P., Montes, Jacqueline, Arbing, Rachel, Vecchio, Darleen, Barsdorf, Alexandra, Mitsumoto, Hiroshi, Levin, Bruce

Volltext

329PAbemaciclib with fulvestrant in patients with HR+, HER2- advanced breast cancer (ABC) that exhibited primary or secondary resistance to prior endocrine therapy (ET) von Grischke, E-M, Neven, P, Lin, Y, Kaufman, P A, Sledge, G W

Volltext

366PReal-world 1-year survival analysis of patients with metastatic breast cancer with liver or lung metastasis treated with eribulin, gemcitabine or capecitabine von Kazmi, S M, Chatterjee, D, Alexis, K, Raju, D, Wang, E, Knoth, R L, Hauser, R S, Kaufman, P A

Volltext

Rex transregulation of human T-cell leukemia virus type II gene expression von KIM, J. H, KAUFMAN, P. A, HANLY, S. M, RIMSKY, L. T, GREENE, W. C

Volltext

LBA6_PRMONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer von Sledge, G W, Toi, M, Neven, P, Sohn, J, Inoue, K, Pivot, X, Burdaeva, O, Okera, M, Masuda, N, Kaufman, P A, Koh, H, Grischke, E-M, Conte, P F, Lu, Y, Barriga, S, Hurt, K, Frenzel, M, Johnston, S R D, Llombart-Cussac, A

Volltext

Phase II trial of tamoxifen, etoposide, mitoxantrone, and cisplatin in patients with metastatic breast carcinoma von Conzen, Suzanne D., Kaufman, Peter A., Arvizu, Christine, LeMarbre, Paul, Maurer, L. Herbert, Mott, Leila A., Mills, Letha E.

Volltext

285PDBalixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial von Cortes Castan, J, Martín, M, Pernas Simon, S, Gomez Pardo, P, Lopez-Tarruella, S, Gil Martin, M, Manso, L M, Ciruelos, E M, Perez Fidalgo, J A, Hernando, C, Ademuyiwa, F, Weilbaecher, K, Mayer, I A, Pluard, T, Martinez Garcia, M, Vahdat, L T, Wach, A, Barker, D, Romagnoli, B, Kaufman, P A

Volltext

Autologous bone marrow transplantation and factor xii, factor vii, and protein c deficiencies report of a new association and its possible relationship to endothelial cell injury von Kaufman, Peter A., Jones, Roy B., Greenberg, Charles S., Peters, William P.

Volltext